Related Experiment Videos
Pharmacotherapy of multiple sclerosis: current status
R A Rudick1, D E Goodkin, R M Ransohoff
1Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195.
Cleveland Clinic Journal of Medicine
|May 1, 1992
Summary
Effective symptomatic treatments are crucial for managing multiple sclerosis (MS). This review examines therapies for MS symptoms like spasticity, fatigue, and pain, alongside corticosteroid use.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Multiple sclerosis (MS) management relies heavily on pharmacotherapy.
- Disease-modifying therapies for MS often show limited efficacy or are experimental.
- Numerous effective symptomatic treatments are available for MS patients.
Purpose of the Study:
- To review the role of pharmacotherapy in multiple sclerosis management.
- To discuss the action and uses of corticosteroids in MS.
- To examine treatment approaches for various MS-related symptoms.
Main Methods:
- Review of existing literature on pharmacotherapy for multiple sclerosis.
- Discussion of corticosteroid mechanisms and applications in MS.
- Examination of symptomatic treatment strategies for specific MS manifestations.
Main Results:
- Corticosteroids have specific actions and uses in multiple sclerosis management.
- Effective symptomatic therapies exist for spasticity, paroxysmal disorders, bladder dysfunction, cerebellar ataxia, neurobehavioral issues, fatigue, and pain in MS.
- While disease-modifying treatments are limited, symptomatic relief is achievable.
Conclusions:
- Pharmacotherapy is essential for comprehensive multiple sclerosis care.
- Symptomatic treatments offer significant benefits for patients with multiple sclerosis.
- Further research into optimizing MS pharmacotherapy, particularly for symptom management, is warranted.